Session: MON 167-198-Hypothalamus-Pituitary Development & Biology
Poster Board MON-193
A retrospective study of patient case records was carried out. A total of 39 adult patients on GH therapy were included. The cause of GH deficiency in 82% of patients was a sellar tumour, congenital GH deficiency in 8%, non-sellar brain tumour in 3%, Sheehan’s syndrome in 3% and cause miscellaneous in 5%. 28 (72%) had baseline AGHDA’s documented. Of the 28 with baseline AGHDA scores, 11 (39%) had a follow up AGHDA score documented within a year of growth hormone treatment. 21 (75%) met the 2003 NICE criteria for GH replacement based on their baseline AGHDA score. Of the 11 with baseline and 1 year AGHDA scores, 5 (45%) warranted continued GH replacement therapy based on their 1 year AGHDA score. The mean baseline AGHDA score was 15 (SD 6.1) and at 1 year was 11.3 (SD 7.3). The average dose of recombinant GH taken daily by adult patients was 0.39mg.
In this study, 75% of the audit population with baseline AGHDA scores documented met the 2003 NICE guideline criteria for GH replacement. However, over a quarter of the audit population did not have a baseline AGHDA documented. 1 year follow up AGHDA scores were documented in less than half of patients who had baseline AGHDA scores documented. In those that had baseline and follow up AGHDA scores documented, over half the patients who continued to receive GH replacement did not meet the NICE guidelines criteria for continuing therapy. This highlights the need for diligent examination and follows up of repeat AGHDA scores to ensure that patients are benefiting from GH treatment and that cost effective measures are observed.
Nothing to Disclose: CK, RC, AAT, DJO
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters